Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hansen

Showing results (1481-1490 of 1,581) with videos related to

Pageof 159
Sort By:
Journal of Neuro-Oncology|April 13, 2019
Evaluation of pediatric glioma outcomes using intraoperative MRI: a multicenter cohort studyMichael Karsy, S Hassan Akbari, David Limbrick, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2019
Chemical disarming of isoniazid resistance in <i>Mycobacterium tuberculosis</i>Kelly Flentie, Gregory A Harrison, Hasan Tükenmez, et al.
Clinical Colorectal Cancer|July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic CancerAlberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2019
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyAurelien Marabelle, Dung T Le, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumorsKirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
Nature Immunology|July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapyGiselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Nature Cancer|February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumabScott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Thrombosis Research|July 21, 1998
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) StudyM R Lassen, L C Borris, B S Anderson, et al.
Pageof 159

Showing results (1481-1490 of 1,581) with videos related to

Sort By:
Pageof 159
Journal of Neuro-Oncology|April 13, 2019
Evaluation of pediatric glioma outcomes using intraoperative MRI: a multicenter cohort studyMichael Karsy, S Hassan Akbari, David Limbrick, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2019
Chemical disarming of isoniazid resistance in <i>Mycobacterium tuberculosis</i>Kelly Flentie, Gregory A Harrison, Hasan Tükenmez, et al.
Clinical Colorectal Cancer|July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic CancerAlberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2019
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyAurelien Marabelle, Dung T Le, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumorsKirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
Nature Immunology|July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapyGiselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Nature Cancer|February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumabScott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Thrombosis Research|July 21, 1998
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) StudyM R Lassen, L C Borris, B S Anderson, et al.
Pageof 159